FOLH1 and neoplasm: To date, the two most used PSMA-targeting small-molecule inhibitors for PSMA-targeted RLT are [177Lu]Lu-PSMA-617 (Pluvicto) and [177Lu]Lu-PSMA I&T which, although different in their chemical structure, exhibit comparable organ biodistribution and rather similar tumor dose [1].